Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma

Cancer Research

Volumn 76, Issue 5, 2016, Pages 1089-1100

  Delgado Calle, Jesus ^a   Anderson, Judith ^a   Cregor, Meloney D ^a   Hiasa, Masahiro ^a   Chirgwin, John M ^a   Carlesso, Nadia ^a   Yoneda, Toshiyuki ^a   Mohammad, Khalid S ^a   Plotkin, Lilian I ^a   Roodman, G David ^a   Bellido, Teresita ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; NOTCH RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; SCLEROSTIN; TUMOR NECROSIS FACTOR ALPHA; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE DESTRUCTION; CELL DIFFERENTIATION; CELL INTERACTION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WESTERN BLOTTING; WNT SIGNALING PATHWAY; ANIMAL; BONE DEVELOPMENT; BONE MARROW; CELL PROLIFERATION; COMPLICATION; CYTOLOGY; ETIOLOGY; FEMALE; GENETIC MARKER; GENETICS; OSTEOBLAST; PATHOLOGY; PHYSIOLOGY;

ANIMALS; APOPTOSIS; BONE MARROW; BONE MORPHOGENETIC PROTEINS; BONE RESORPTION; CELL PROLIFERATION; CELLULAR MICROENVIRONMENT; FEMALE; GENETIC MARKERS; HUMANS; MICE; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOCYTES; OSTEOGENESIS; RANK LIGAND; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84961683824     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1703     Document Type: Article

References (51)

1. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 2009; 23:435-41.
2. Greenberg AJ, Rajkumar SV, Therneau T.M., Singh PP, Dispenzieri A, Kumar SK. Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia 2014; 28:398-403.
3. Roodman GD. Targeting the bone microenvironment in multiple myeloma. J Bone Miner Metab 2010; 28:244-50.
4. Andersen TL, Soe K, Sondergaard T.E., Plesner T., Delaisse JM. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells. Br J Haematol 2010; 148:551-61.
5. Giuliani N, Colla S, Morandi F., Lazzaretti M, Sala R, Bonomini S., et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005; 106:2472-83.
6. Bellido T. Osteocyte-driven bone remodeling. Calcif Tissue Int 2013; 94: 25-34.
7. Ke HZ, Richards WG, Li X, Ominsky MS Sclerostin and dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012; 33:747-83.
8. Van Bezooijen R.L., Roelen BA, Visser A, Wee-Pals L, de Wilt E, Karperien M, et al Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004; 199: 805-14.
9. Bonewald LF. The amazing osteocyte. J Bone Miner Res 2011; 26:229-38.
10. Li X, Ominsky MS, Niu Q.T., Sun N., Daugherty B, D'Agostin D, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008; 23:860-9.
11. O'Brien C.A., Nakashima T, Takayanagi H. Osteocyte control of osteoclas-togenesis. Bone 2013; 54:258-63.
12. Balemans W, Ebeling M, Patel N., Van Hul E, Olson P, Dioszegi M., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001; 10:537-43.
13. Bellido T. Osteocyte apoptosis induces bone resorption and impairs the skeletal response to weightlessness. Bonekey-osteovision 2007; 4:252-6.
14. Kato Y, Boskey A, Spevak L., Dallas M, Hori M, Bonewald LF Establishment of an osteoid preosteocyte-like cell MLO-A5 that spontaneously mineralizes in culture. J Bone Miner Res 2001; 16:1622-33.
15. Kato Y, Windle JJ, Koop B.A., Mundy GR, Bonewald LF. Establishment of an osteocyte-like cell line, MLO-Y4. J Bone Miner Res 1997; 12: 2014-23.
16. D'Souza S., del PD, Jin S, Sun Q., Huston AJ, Kostov FE, et al. Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease. Blood 2011; 118:6871-80.
17. Giuliani N, Ferretti M, Bolzoni M., Storti P, Lazzaretti M, Dalla P.B., et al. Increased osteocyte death inmultiple myeloma patients: role inmyeloma-induced osteoclast formation. Leukemia 2012; 26:1391-401.
18. Greenstein S, Krett NL, Kurosawa Y, Ma C., Chauhan D, Hideshima T, et al Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and - resistant MM cells. Exp Hematol 2003; 31:271-82.
19. Lecka-Czernik B., Gubrij I, Moerman E.A., Kajkenova O., Lipschitz DA, Manolagas SC, et al. Inhibition of Osf2/Cbfa1 expression and terminal osteo-blast differentiation by PPAR-gamma 2. J Cell Biochem 1999; 74:357-71.
20. Pacheco-Costa R., Hassan I, Reginato R.D., Davis HM, Bruzzaniti A, Allen MR, et al High bone mass in mice lacking Cx37 due to defective osteoclast differentiation. J Biol Chem 2014; 289:8508-20.
21. Suvannasankha A, Tompkins DR, Edwards D.F., Petyaykina KV, Crean CD, Fournier PG, et al FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells. Oncotarget 2015; 6:19647-60.
22. Bellido T, Plotkin LI Detection of apoptosis of bone cells in vitro. In: Westendorf JJ, editor. Osteoporosis. Clifton, NJ, USA: Humana Press; 2007. p. 51-75.
23. Kousteni S, Bellido T, Plotkin L.I., O'Brien CA, Bodenner DL, Han L, et al Nongenotropic, sex-nonspecific signaling through the estrogen or and rogen receptors: dissociation from transcriptional activity. Cell 2001; 104: 719-30.
24. Bivi N, Lezcano V, Romanello M., Bellido T, Plotkin LI. Connexin43 interacts with barrestin: a pre-requisite for osteoblast survival induced by parathyroid hormone. J Cell Biochem 2011; 112:2920-30.
25. Tu X, Delgado-Calle J, Condon K.W., Maycas M., Zhang H, Carlesso N, et al Osteocytes mediate the anabolic actions of canonica Wnt/b-catenin signaling in bone. Proc Natl Acad Sci U S A 2015; 112:E478-86.
26. Al-Dujaili S.A., Lau E, Al-Dujaili H, Tsang K., Guenther A, You L. Apoptotic osteocytes regulate osteoclast precursor recruitment and differentiation in vitro. J Cell Biochem 2011; 112:2412-23.
27. Kubek DJ, Gattone VH, Allen MR Methodological assessment of acid-etching for visualizing the osteocyte lacunar-canalicular networks using scanning electron microscopy. Microsc Res Tech 2010; 73:182-6.
28. Bray SJ. Notch signalling: asimple pathway becomescomplex. Nat RevMol Cell Biol 2006; 7:678-89.
29. Houde C, Li Y, Song L., Barton K, Zhang Q, Godwin J., et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 2004; 104:3697-704.
30. Jundt F, Probsting KS, Anagnostopoulos I, Muehlinghaus G., Chatterjee M, Mathas S, et al Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004; 103:3511-5.
31. Jilka RL, Bellido T, Almeida M., Plotkin LI, O'Brien CA, Weinstein RS, et al Apoptosis in bone cells. In: Bilezikian JP, Raisz LG, Martin TJ, editors. Principles of bone biology. 3rd ed. San Diego, San Francisco, New York, London, Sydney, Tokyo: Academic Press; 2008. p. 237-61.
32. Aggarwal R, Ghobrial IM, Roodman GD Chemokines in multiple myeloma. Exp Hematol 2006; 34:1289-95.
33. Yochum GS, McWeeney S, Rajaraman V., Cleland R, Peters S, Goodman RH. Serial analysis of chromatin occupancy identifies beta-catenin target genes in colorectal carcinoma cells. Proc Natl Acad Sci U S A 2007; 104:3324-9.
34. O'Brien C.A., Plotkin LI, Galli C, Goellner J., Gortazar AR, Allen MR, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE 2008; 3:e2942.
35. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 2013; 19:179-92.
36. Colombo M, Mirandola L, Platonova N., Apicella L, Basile A, Figueroa A.J., et al. Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes. Leukemia 2013; 27:1009-18.
37. Nefedova Y, Sullivan DM, Bolick S.C., Dalton WS, Gabrilovich DI. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 2008; 111:2220-9.
38. Guo D, Li C, Teng Q., Sun Z, Li Y, Zhang C. Notch1 overexpression promotes cell growth and tumor angiogenesis in myeloma. Neoplasma 2013; 60:33-40.
39. Chiron D, Maiga S, Descamps G., Moreau P, Le GS, Marionneau S, et al Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. Blood Cells Mol Dis 2012; 48:247-53.
40. Xu D, Hu J, Xu S., De BE, Menu E, Van CB, et al Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation. Leukemia 2012; 26:1402-5.
41. Mungamuri SK, Yang X, Thor A.D., Somasundaram K. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 2006; 66:4715-24.
42. Yang X, Klein R, Tian X., Cheng HT, Kopan R, Shen J. Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway. Dev Biol 2004; 269:81-94.
43. Chadwick N, Nostro MC, Baron M, Mottram R., Brady G, Buckle AM. Notch signaling induces apoptosis in primary human CD34+ hematopoietic progenitor cells. Stem Cells 2007; 25:203-10.
44. Almeida M, Han L, Bellido T., Manolagas SC, Kousteni S. Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and - independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem 2005; 280:41342-51.
45. Ming M, Wang S, Wu W., Senyuk V, Le Beau MM, Nucifora G, et al. Activation of Wnt/beta-catenin protein signaling induces mitochondria-mediated apoptosis in hematopoietic progenitor cells. J Biol Chem 2012; 287:22683-90.
46. Zimmerman ZF, Kulikauskas RM, Bomsztyk K, Moon R.T., Chien AJ. Activation of Wnt/beta-catenin signaling increases apoptosis in melanoma cells treated with trail. PLoS ONE 2013; 8:e69593.
47. Terpos E, Christoulas D, Katodritou E., Bratengeier C, Gkotzamanidou M, Michalis E., et al. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer 2012; 131:1466-71.
48. Brunetti G, Oranger A, Mori G., Specchia G, Rinaldi E, Curci P., et al. Sclerostin is overexpressed by plasma cells from multiple myeloma patients. Ann N Y Acad Sci 2011; 1237:19-23.
49. Bianchi G, Munshi NC Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood 2015; 125:3049-58.
50. Li M, Chen F, Clifton N., Sullivan DM, Dalton WS, Gabrilovich DI, et al Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect. Mol Cancer Ther 2010; 9:3200-9.
51. Schwarzer R, Nickel N, Godau J., Willie BM, Duda GN, Schwarzer R, et al Notch pathway inhibition controls myeloma bone disease in the murine MOPC315. BM model. Blood Cancer J 2014; 4:e217.